Möchten Sie immer auf dem neuesten Stand bleiben?

Avertix to Participate in the BTIG Digital Health Forum

Patients with Guardian™ System alarms active experienced a substantial increase in new prescriptions or medication adjustments related to rate and rhythm abnormalities, with 29.0% of Alarms ON...

EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving...

EATONTOWN, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease...

The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to...

Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing...

EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving...

EATONTOWN, N.J. and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk...

- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac...

New company name chosen to represent focus on ‘averting’ serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President and CEO Tim Moran and Chief Financial...